Literature DB >> 20844694

Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder.

Martin P Cruz.   

Abstract

Entities:  

Year:  2010        PMID： 20844694      PMCID： PMC2935643     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  11 in total

Review 1.  Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics.

Authors: 
Journal:  Pediatrics       Date:  2000-05       Impact factor: 7.124

2.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

3.  Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.

Authors:  James M Perrin; Richard A Friedman; Timothy K Knilans
Journal:  Pediatrics       Date:  2008-08       Impact factor: 7.124

Review 4.  Pharmacokinetics and metabolism of guanfacine in man: a review.

Authors:  J R Kiechel
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

5.  Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Floyd R Sallee; Andrew Lyne; Timothy Wigal; James J McGough
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-06       Impact factor: 2.576

6.  A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Joseph Biederman; Raun D Melmed; Anil Patel; Keith McBurnett; Jennifer Konow; Andrew Lyne; Noreen Scherer
Journal:  Pediatrics       Date:  2008-01       Impact factor: 7.124

7.  Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.

Authors:  Victoria L Vetter; Josephine Elia; Christopher Erickson; Stuart Berger; Nathan Blum; Karen Uzark; Catherine L Webb
Journal:  Circulation       Date:  2008-04-21       Impact factor: 29.690

8.  Pharmacokinetics of guanfacine in patients with impaired renal function and in some elderly patients.

Authors:  J R Kiechel
Journal:  Am J Cardiol       Date:  1986-03-28       Impact factor: 2.778

Review 9.  Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Steven Pliszka
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2007-07       Impact factor: 8.829

10.  The influence of renal function on plasma concentration, urinary excretion and antihypertensive effect of guanfacine.

Authors:  W Kirch; H Köhler; W Braun; C von Gizycki
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447
View more
  3 in total

1.  Focus on Guanfacine Extended-release: A Review of its Use in Child and Adolescent Psychiatry.

Authors:  Dean Elbe; Dorothy Reddy
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2014-02

Review 2.  Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy.

Authors:  Toyosaku Ota; Kazuhiko Yamamuro; Kosuke Okazaki; Toshifumi Kishimoto
Journal:  Drug Des Devel Ther       Date:  2021-05-11       Impact factor: 4.162

Review 3.  ADHD and adolescent athletes.

Authors:  Ahsan Nazeer; Miriam Mansour; Kathleen A Gross
Journal:  Front Public Health       Date:  2014-06-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.